Reports Q4 revenue $430M, consensus $379.42M. “2024 marked the completion of a multi-year effort to transition the business into a highly ...

Avadel Pharmaceuticals' stock is undervalued due to peak sales potential, along with the possibility of a buyout. Click here ...

Since launching in 2017, Plymouth Meeting’s Harmony Biosciences has grown from a small drug developer into a billion-dollar company, writes John ...

Like millions of other Americans, Kelsey Hameister's mood is impacted by the change of seasons. Two in every five say their ...

Equities research analysts at Roth Capital issued their FY2029 earnings per share estimates for Zevra Therapeutics in a note issued to investors on Sunday, February 9th. Roth Capital analyst J.

Deutsche Bank (ETR:DBKGn) initiated coverage on Alkermes (NASDAQ:ALKS) shares with a Buy rating and a price target of $40.00.

The following is a letter that ASL Strategic Value Fund sent to the Board of Directors of Avadel Pharmaceuticals (NASDAQ:AVDL): Mr.

Beyond analysts' top -and-bottom-line estimates for Alkermes (ALKS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the ...

After hours: 7:59:57 p.m. EST ...